701P Multicenter analysis of first-line (1L) regimens (BEP vs VIP) in patients (pts) with non-seminomatous germ cell tumors (NSGCTs) who subsequently underwent high-dose chemotherapy (HDCT). Read more about 701P Multicenter analysis of first-line (1L) regimens (BEP vs VIP) in patients (pts) with non-seminomatous germ cell tumors (NSGCTs) who subsequently underwent high-dose chemotherapy (HDCT).
381P Treatment rechallenge after grade 1 trastuzumab-deruxtecan related interstitial lung disease: A real-world experience. Read more about 381P Treatment rechallenge after grade 1 trastuzumab-deruxtecan related interstitial lung disease: A real-world experience.
67O Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity. Read more about 67O Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity.
356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study. Read more about 356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study.
1751P Impact of squamous histology on clinical outcomes and molecular profiling in metastatic urothelial carcinoma (mUC) patients (pts) treated with newer therapies. Read more about 1751P Impact of squamous histology on clinical outcomes and molecular profiling in metastatic urothelial carcinoma (mUC) patients (pts) treated with newer therapies.
1404P A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration resistant prostate cancer (mCRPC): Interim safety results. Read more about 1404P A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration resistant prostate cancer (mCRPC): Interim safety results.
1379P A phase Ib study of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC). Read more about 1379P A phase Ib study of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC).
1229P A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers. Read more about 1229P A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers.
95P Serum-based colorectal cancer detection using orphan noncoding RNAs. Read more about 95P Serum-based colorectal cancer detection using orphan noncoding RNAs.
1571P COVID-19 positivity rates in patients with an active cancer diagnosis in the University of California Cancer Consortium. Read more about 1571P COVID-19 positivity rates in patients with an active cancer diagnosis in the University of California Cancer Consortium.
